Operator's Information

Gregg W. Stone, MD

Country USA
Specialty Interventional Cardiologist
  1. Interatrial Shunt Treatment for Heart Failure
  2. Left Main and Multi-Vessel Revascularization 2025: Updated Guidelines and Beyond
  3. Impella Support During High-Risk PCI: PROTECT IV
  4. Imaging Outcomes From Meta-Analysis, ILUMIEN IV and ECLIPSE
  5. A Novel Ongoing Trial of PCI vs. CABG: RECHARGE
  6. MitraClip Treatment of Secondary MR in Heart Failure: Final 5-Year Results from COAPT
  7. BRIGHT-4 Trial; Bivalirudin with a Post-PCI High-Dose Infusion vs. Heparin Monotherapy During Primary PCI in STEMI
  8. How to Treat: Left Main & 3 Vessel Disease
  9. Left Main Revascularization: Data Supports PCI in Most Cases
  10. Which Patients with Stable CAD Benefit from PCI in the Post-ISCHEMIA Era?
  11. Left Main PCI vs. CABG: Form the Final EXCEL Outcomes to Patient Recommendations
  12. Transcatheter Mitral Valve Repair: Guideline Changes, Evidence Gaps and Future Directions
  13. New Insights from the COAPT: Patient Eligibility and Timing
  14. EXCEL Trial: Extended Long-term and Key Clinical Substudies
  15. Mitral Valve: Future Perspectives
  16. Long-term and Updated Data from EXCEL and NOBLE
  17. ONYX One and ONYX One CLEAR Trials of 1-month DAPT After Onyx
  18. The COAPT Trial: How the Trial Succeed?
  19. Deep Dive into Mitraclip Trials for Functional MR
  20. Long-term Outcomes and More Data from ABSORB Trials
  21. FFRCT to Guide Revascularization Decisions: The DECISION Trial
  22. COAPT
  23. Inter-Atrial Shunts in HF: Devices, Indication, and Outcomes
  24. Future Perspectives of BRS, Will It Go Forward or Not?
  25. XIENCE Safety ; Review of XIENCE DAPT Clinical Evidence and Clinical Program
  26. ABSORB IV: 30-day Outcomes from a Randomized Trial of a Bioresorbable Scaffold Versus a Metallic DES in Patients with Coronary Artery Disease
  27. ABSORB III, IV, Updated Meta, and More - Expert Future Expectation on Bioabsorbable Scaffolds
  28. Clinical Trials in Functional Mitral Regurgitation
  29. [Satellite Lecture] PCI Outcomes with Bioresorbable Scaffolds: Role of Technique and DAPT
  30. [Satellite Lecture]Congratulatory Remark & Keynote Lecture: “Left Main Intervention Comes of Age: A 40-Year Odyssey from Balloon Angioplasty to Drug-Eluting Stents”
  31. The Future PROSPECT for the Role of Antiplatelet Therapy
  32. Why Do We Need a Fully Bioresorbable Vascular Scaffold; From Absorb III and ABSORB Meta-Analysis to the Future
  33. ABSORB III - Current and Future Use of Bioresorbable Scaffolds
  34. Drug-Eluting Stents vs. Bioresorbable Vascular Scaffolds: Is Newer Better?  
  35. Management of Stable Coronary Heart Disease with Objective Ischemia: COURAGE, FAME2 and Recent Meta-Analysis
  36. BRS: From ABSORB III to the Future
  37. Left Main PCI: Anticipating EXCEL
  38. PLATO: Impact on the Management of ACS and Personalizing Treatment with Ticagrelor
  39. Evolution, BVS Unique Benefits, Clinical Perspectives on Angina
  40. UFH Versus Bivalirudin: Which One Should I Use?
  41. Focal Treatment of Vulnerable Plaque: Stents, Scaffolds and Prospect II
  42. Future Roadmap of the Mitral Valve Therapies
  43. Vulnerable Plaque Detection and Treatment: PROSPECT II and PROSPECT ABSORB
  44. Bioresorbable Scaffolds in a "Nutshell": Updates and Expectations
  45. Lessons from the Pooled Data using Xience Everolimus-eluting Stent
  46. Evidence-based Pharmacotherapy for ACS Patients: The Forest and the Trees
  47. Reduction of Thrombus: Routine vs. Selective Aspiration
  48. Current Status of EXCEL Study
  49. New Insights Regarding the Safety and Efficacy of DAPT After Stenting
  50. Latest Update of PLATINUM Trial: Promus Element Workhorse Two Year Follow-up
  51. PCI Today: Best Practices, Optimal Outcomes, and Limitations: When Do I Prefer CABG for MVD?
  52. What’s Known and Unknown about LM PCI: Transitioning from SYNTAX to EXCEL
  53. PLATINUM Workhorse Data from ACC
  54. Xience Platform Safey Update
  55. Everolimus-Eluting versus Paclitaxel-Eluting Stents in Coronary Artery Disease (SPIRIT IV)
  56. The EXCEL Trial
  57. DES in Left Main Disease: New Guidelines and Updates from EXCEL
  58. Motivation, Objective and Implication of EXCEL Study
  59. Bioabsorble or Free-Polymer DES: Current and New Technologies
  60. Milestone for Left Main PCI: Upcoming Excel LM Trial
  61. Does PROSPECT Support the Use of Invasive Imaging to Diagnose and Treat Vulnerable Plaque with DES?
  62. Introducing EXCEL: The "Definitive" Unprotected Left Main Randomized Trial!
  63. The Latest Updates in DES Clinical Data
  64. STEMI and NSTEMI Pharmacology Confusion: How to Choose and Use Antithrombins (Unfractionated and Low Molecular Weight Heparins, Bivalirudin, Fondaparinux) and Antiplatelet Agents (Aspirin, Clopidogrel, and Prasugrel)
  65. Linkage of Current Plaque Vulnerability to Future Events: Evidence from PROSPECT Study
  66. HORIZONS AMI: A Large Prospective Randomized Trial of PES vs. BMS in Patients with STEMI
  67. Comparison of DES versus BMS in Real World Registries
  68. New Paradigms of Care for ST-Elevation Myocardial Infarction (STEMI): Focusing on Mortality and Attributable Death Analysis in Cath-Based Care: What Do Device and Drug Trials Teach Us?
  69. Revived Indications for Thrombus Aspiration During Primary PCI: Unanswered Questions after TAPAS
  70. HORIZONS AMI: Implications for Pharmaco-Adjunctive Therapy and DES Use
  71. HORIZONS AMI AMI: Prospective Randomized Trials of Paclitaxel-Eluting Stents vs. BMS in Patients with STEMI
  72. COOL RCN : Randomized Trail of Systemic Hypothermia for Prevention of Radiocontrast Nephropathy
  73. Bivalirudin for the Best Overall Outcomes and Most Cath Lab Compatible
  74. SPIRIT III (US Pivotal Study Results for Xience V Everolimus Eluting Coronary Stent)
  75. Taking the Evidence-Based Approach to ACS: Examination of New Antithrombin Trial Data
  76. SPIRIT-III: Clinical, Angiographic and IVUS Results from the Pivotal United States Randomized SPIRIT-III Trial of the Xience V Everolimus Eluting Coronary Stent System in Patients With Coronary Artery Disease
  77. ACUITY PCI: A Prospective Trial of Patients With Acute Coronary Syndromes Undergoing PCI After Randomization to Heparin Plus Glycoprotein IIb/IIIa Inhibitors vs Bivalirudin With or Without Glycoprotein IIb/IIIa Inhibitors: 30-Day Clinical and Angiographic Core Laboratory Results
  78. The Baseline Clinical Features and Plaque Characteristics from the PROSPECT Trial
  79. Should DES Use be Reduced Due to Safety Concerns? Important Messages from the Randomized DES Trials
  80. 2007 Guidelines Update for DES: An Evidence-Based Medicine Critical Analysis
  81. Evidence-Based Medicine Analysis of Current DES Clinical Use Guidelines: A Roadmap for Clinicians
  82. Taxus V Clinical Update
  83. Optimizing Outcomes of Primary PCI: From CADILLAC to HORIZONS
  84. EMERALD Trial: Lessons Learned
  85. Zen Philosophy - The KEY to CTO Success
  86. Evidence-Based Medicine Analysis of Current DES Clinical
  87. Recent Updates from the Taxus Trials (Taxus 2 and 4 Late FU, Taxus Meta-Analysis, and Taxus 5)
  88. Paclitaxel-Eluting TAXUS Stents Strengths and Weaknesses
Conference Slides
Category